Age-related differences in the pharmacokinetics of stavudine in 272 children from birth to 16 years: A population analysis

British Journal of Clinical Pharmacology

Volumn 64, Issue 1, 2007, Pages 105-109

  Jullien, V ^a,b,c,e,j   Rais A ^a,b,c,e   Urien, S ^g,j   Dimet, J ⁱ   Delaugerre, C ^a,b,d,h   Bouillon Pichault, M ^a,c,e,j   Rey, E ^a,b,c,e,j   Pons, G ^a,b,c,e,j   Blanche, S ^a,b,d,f,j   Treluyer J M ^a,b,c,e,j  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^c Institut Cochin   (France)

^d HÔPITAL NECKER ENFANTS MALADES   (France)

^e Pharmacologie Clinique   (France)

^f Unité d'Immunologie Pédiatrique   (France)

^g Centre Hospitalier René Huguenin   (France)

^h Virologie ^*  (France)

ⁱ Unité de Recherche Clinique la Roche sur Yon   (France)

^j EA   (France)

more..

Author keywords

Children; HIV; Pharmacokinetics; Stavudine

Indexed keywords

STAVUDINE;

ADOLESCENT; AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT; CHILD; CHILDHOOD DISEASE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; MAJOR CLINICAL STUDY; NEWBORN; PLASMA CLEARANCE; POPULATION RESEARCH; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; TREATMENT DURATION; VIRUS TRANSMISSION;

ADOLESCENT; AGE FACTORS; ANTI-HIV AGENTS; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; HIV INFECTIONS; HUMANS; INFANT, NEWBORN; MODELS, BIOLOGICAL; STAVUDINE;

EID: 34250686096     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2007.02854.x     Document Type: Article

References (14)

1. Kaul S, Kline MW, Church JA, Dunkle LM. Determination of dosing guidelines for stavudine (2′,3′-didehydro-3′-deoxythymidine) in children with human immunodeficiency virus infection. Antimicrob Agents Chemother 2001 45 : 758 63.
2. Fletcher CV, Brundage RC, Remmel RP, Page LM, Weller D, Calles NR, Simon C, Kline MW. Pharmacologic characteristics of indinavir, didanosine, and stavudine in human immunodeficiency virus-infected children receiving combination therapy. Antimicrob Agents Chemother 2000 44 : 1029 34.
3. Wade NA, Unadkat JD, Huang S, Shapiro DE, Mathias A, Yasin S, Ciupak G, Watts DH, Delke I, Rathore M, Hitti J, Frenkel L, Samelson R, Smith ME, Mofenson L, Burchett SK. Pharmacokinetics and safety of stavudine in HIV-infected pregnant women and their infants: Pediatric AIDS Clinical Trials Group protocol 332. J Infect Dis 2004 190 : 2167 74.
4. Kline MW, Dunkle LM, Church JA, Goldsmith JC, Harris AT, Federici ME, Schultze ME, Woods L, Loewen DF, Kaul S, et al. A phase I/II evaluation of stavudine (d4T) in children with human immunodeficiency virus infection. Pediatrics 1995 96 (2 Part 1 247 52.
5. Rongkavilit C, Thaithumyanon P, Chuenyam T, Damle BD, Limpongsanurak S, Boonrod C, Srigitsanapol A, Hassink EA, Hoetelmans RM, Cooper DA, Lange JM, Ruxrungtham K, Phanuphak P. Pharmacokinetics of stavudine and didanosine coadministered with nelfinavir in human immunodeficiency virus-exposed neonates. Antimicrob Agents Chemother 2001 45 : 3585 90.
6. Beal SL, Sheiner LB. NONMEM User's Guide. NONMEM Project Group. San Francisco, University of California at San Francisco, 1991.
7. Jullien V, Treluyer JM, Chappuy H, Dimet J, Rey E, Dupin N, Salmon D, Pons G, Urien S. Weight related differences in the pharmacokinetics of abacavir in HIV-infected patients. Br J Clin Pharmacol 2005 59 : 183 8.
8. Seifert RD, Stewart MB, Sramek JJ, Conrad J, Kaul S, Cutler NR. Pharmacokinetics of co-administered didanosine and stavudine in HIV-seropositive male patients. Br J Clin Pharmacol 1994 38 : 405 10.
9. Kaul S, Mummaneni V, Barbhaiya RH. Dose proportionality of stavudine in HIV seropositive asymptomatic subjects: application to bioequivalence assessment of various capsule formulations. Biopharm Drug Dispos 1995 16 : 125 36.
10. Anderson BJ, Woollard GA, Holford NH. A model for size and age changes in the pharmacokinetics of paracetamol in neonates, infants and children. Br J Clin Pharmacol 2000 50 : 125 34.
11. Dudley MN, Graham KK, Kaul S, Geletko S, Dunkle L, Browne M, Mayer K. Pharmacokinetics of stavudine in patients with AIDS or AIDS-related complex. J Infect Dis 1992 166 : 480 5.
12. Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE. Developmental pharmacology - drug disposition, action, and therapy in infants and children. N Engl J Med 2003 349 : 1157 67.
13. Horton CM, Dudley MN, Kaul S, Mayer KH, Squires K, Dunkle L, Anderson R. Population pharmacokinetics of stavudine (d4T) in patients with AIDS or advanced AIDS-related complex. Antimicrob Agents Chemother 1995 39 : 2309 15.
14. Becher F, Landman R, Mboup S, Kane CN, Canestri A, Liegeois F, Vray M, Prevot MH, Leleu G, Benech H. Monitoring of didanosine and stavudine intracellular trisphosphorylated anabolite concentrations in HIV-infected patients. AIDS 2004 18 : 181 7.